Ambry Genetics
2024 CNS Annual Corporate Partner
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
For child neurologists and others who guide healthcare decisions for children with rare diseases, neurodevelopmental disorders, and epilepsy, Ambry Genetics offers a complete suite of genetic testing. Our portfolio includes exome testing with ExomeRevealTM, which offers a 20% increase in diagnostic yield over standard exomes by adding both RNA analysis and lab-driven, continuous reanalysis through our Patient for LifeTM program. We also offer chromosomal microarray testing (SNPArray), fragile X testing, and multi-gene panels designed for autism, epilepsy, and neurodevelopmental disorders.
Learn More at: http://ambrygen.com